Form 8-K - Current report:
SEC Accession No. 0001104659-24-127487
Filing Date
2024-12-11
Accepted
2024-12-11 09:05:07
Documents
15
Period of Report
2024-12-10
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430732d1_8k.htm   iXBRL 8-K 35093
2 EXHIBIT 99.1 tm2430732d1_ex99-1.htm EX-99.1 18056
6 GRAPHIC tm2430732d1_ex99-1img001.jpg GRAPHIC 13735
  Complete submission text file 0001104659-24-127487.txt   253619

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA clrb-20241210.xsd EX-101.SCH 3018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20241210_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20241210_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2430732d1_8k_htm.xml XML 3568
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36598 | Film No.: 241540340
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)